Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-26T00:20:16.614Z Has data issue: false hasContentIssue false

P.068 Discrepancy between post-treatment infarct volume and 90-day outcome in ischemic stroke: A validation study in the ESCAPE-NA1 randomized controlled trial

Published online by Cambridge University Press:  05 January 2022

A Ganesh
Affiliation:
(Calgary)*
JM Ospel
Affiliation:
(Basel)
BK Menon
Affiliation:
(Calgary)
AM Demchuk
Affiliation:
(Calgary)
RG Nogueira
Affiliation:
(Atlanta)
RA McTaggart
Affiliation:
(Providence)
AY Poppe
Affiliation:
(Montreal)
MA Almekhlafi
Affiliation:
(Calgary)
RA Hanel
Affiliation:
(Jacksonville)
G Thomalla
Affiliation:
(Hamburg)
S Holmin
Affiliation:
(Stockholm)
V Puetz
Affiliation:
(Dresden)
BA van Adel
Affiliation:
(Hamilton)
JW Tarpley
Affiliation:
(Torrance)
M Tymianski
Affiliation:
(Toronto)
MD Hill
Affiliation:
(Calgary)
M Goyal
Affiliation:
(Calgary)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Some patients do poorly despite small infarcts after endovascular therapy(EVT) whilst others with large infarcts do well. We validated exploratory findings from the ESCAPE trial regarding factors associated with such discrepancies, in the ESCAPE-NA1 trial(NCT02930018). Methods: We identified “discrepant cases” with modified Rankin Scale(mRS)≥3 despite small follow-up infarct volume(FIV≤25th-percentile) on 24-hour CT/MRI or mRS≤2 despite large FIV(volume≥75th-percentile). We compared area-under-the-curve(AUC) of pre-specified logistic models containing (a)pre-treatment factors(age/cancer/vascular risk-factors) and (b)treatment-related/post-treatment factors(serious adverse events/SAEs) in identifying small-FIV/mRS≥3 and large-FIV/mRS≤2, with stepwise regression-derived models. Results: Among 1,091 patients, 42/287(14.6%) with FIV≤7mL(25th-percentile) had mRS≥3; 65/275(23.6%) with FIV≥92mL(75th-percentile) had mRS≤2. Pre-specified pre-treatment factors(age/cancer/vascular risk-factors) were associated with FIV≤7mL/mRS≥3; stepwise models selected similar variables(similar AUCs:0.92-0.93,p=0.42). SAEs(infarct-in-new-territory/recurrent stroke/pneumonia/heart failure) were strongly associated with FIV≤7mL/mRS≥3; stepwise models also identified onset-to-needle time and hemoglobin(24-hours) as treatment-related/post-treatment factors(similar AUCs:0.92-0.94,p=0.14). Younger age was associated with FIV≥92mL/mRS≤2; stepwise models also selected diabetes absence and baseline hemoglobin(similar AUCs:0.76-0.77,p=0.82). Absence of SAEs(stroke progression/pneumonia/intracerebral hemorrhage) was strongly associated with FIV≥92mL/mRS≤2; stepwise models also identified 24-hour hemoglobin, glucose, and BP(similar AUCs:0.79-0.80,p=0.030). Conclusions: FIV-mRS discrepancies are associated with pre-treatment factors like age/comorbidities; and post-treatment complications related to stroke evolution, secondary prevention, and post-acute care quality. Optimizing thrombolysis speed, BP, glucose, and hemoglobin are modifiable factors meriting further study.

Type
Poster Presentations
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation